ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

NMDP Hires New Leaders to Executive Team to Continue Advancing Five-Year Strategic Plan

New Chief Financial and Chief Information Officers to Extend Global Cell Therapy Nonprofit’s Operational Excellence in its Quest to Find More Cures and Save More Lives

NMDPSM, a global nonprofit leader in cell therapy, announced today it hired two new executives – Katherine Heyerdahl as chief financial officer (CFO) and Jim Graham as chief information officer (CIO) – to its executive team, where they will play pivotal roles in driving the organization’s mission-critical operational strategy. Heyerdahl and Graham are filling existing executive leadership roles.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240621400378/en/

Katherine Heyerdahl, chief financial officer, NMDP (Photo: Business Wire)

Katherine Heyerdahl, chief financial officer, NMDP (Photo: Business Wire)

“We have an ambitious, bold vision to accelerate our global impact in the next five years and impact 10,000 lives annually via life-saving stem cell therapy,” said Amy Ronneberg, CEO of NMDP. “Ensuring every patient with blood cancers and disorders has access to the life-saving cell therapy they deserve requires a proven leadership team relentlessly focused on operational excellence and execution.”

Graham will join the organization on July 8 and will lead all aspects of information technology, including modernizing and scaling platforms and maintaining system security, automation and operational efficiencies. Most recently, he spent 11 years at Prime Therapeutics, a Twin Cities-based pharmacy benefit management company. As CIO, he led a multi-year initiative to modernize and scale technology platforms during a new operating model implementation, which helped improve speed-to-market, state-of-the-art automation, and access to information. Before Prime, Graham spent over a decade in executive IT roles at Voya Financial, formerly ING.

Heyerdahl joined NMDP April 22, spearheading the organization’s financial sustainability – one of NMDP’s key operating metrics – as well as on pricing for its products and services. She most recently served as chief strategy officer for the Individual and Family Plans business at UnitedHealth Group (UHG), where she delivered on a new market expansion strategy, long-term business plan and capital portfolio for UHG’s Healthcare Exchange business. Previously, she held various leadership roles within the Optum segment of UHG, The Travelers Companies and Deloitte & Touche.

“Katherine and Jim are stepping into critical roles, with NMDP at the precipice of unparalleled growth. They not only bring deep healthcare expertise to our bench of talent, they are also respected as mission-driven, operational leaders and experienced stewards of the resources needed to advance cell therapy research, deliver best-in-class service and expand equitable access to life-saving cell therapy,” Ronneberg added. “We’re thrilled they are joining us to help find more cures and save more lives.”

About NMDPSM

At NMDPSM, we believe each of us holds the key to curing blood cancers and disorders. As a global nonprofit leader in cell therapy, NMDP creates essential connections between researchers and supporters to inspire action and accelerate innovation to find life-saving cures. With the help of blood stem cell donors from the world’s most diverse registry and our extensive network of transplant partners, physicians and caregivers, we’re expanding access to treatment so that every patient can receive their life-saving cell therapy. NMDP. Find cures. Save lives. Learn more at nmdp.org.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.